Morgan Stanley lowered the firm’s price target on Absci (ABSI) to $4.10 from $4.20 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci price target raised to $11 from $9 at JonesResearch
- AbSci Price Target Raised to $11 as Analyst Reiterates Buy on Promising PRLR Pipeline and ABS-201 Data
- Absci Corp. Charts High-Stakes Path With ABS-201
- Absci’s ABS-201 Hair-Loss Trial Moves Forward: What Early-Stage Data Could Mean for ABSI
- Brendan Smith Reiterates Buy on AbSci, Citing Emerging PRLR Franchise and Multiple Upcoming Clinical Catalysts